Utilidad del enalapril, inhibidor de la enzima convertidora de la angiotensiva, en la hipertensión arterial pulmonar

Escudero, Jorge; Navarro, José; Betancourt, Lidia; Nava, Guillermo; Padua, Antonio.
Arch. Inst. Cardiol. Méx ; 56(6): 467-73, nov.-dic. 1986. ilus, tab
Artículo en Español | LILACS | ID: lil-47213

Documentos relacionados

  1. Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria.
  2. Sleep Outcomes From AWAKE-HF: A Randomized Clinical Trial of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
  3. Safety of Enalapril in Infants: Data from the Pediatric Heart Network Infant Single Ventricle Trial.
  4. Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs.
  5. Safety and efficacy of intralesional injection of enalapril versus triamcinolone acetonide in the treatment of keloids.
  6. Experimental evaluation of Enalapril effect on protein oxidative modification, proteolytic processes and cerebral morphological changes in rats with type 2 diabetes mellitus.
  7. Interaction of neutrophil counts and folic acid treatment on new-onset proteinuria in hypertensive patients.
  8. Successful management of hypertrophic cardiomyopathy in a Matschie's tree kangaroo (Dendrolagus matschiei).
  9. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease.
  10. Efficacy of felodipine and enalapril in the treatment of essential hypertension with coronary artery disease and the effect on levels of Salusin-ß, Apelin, and PON1 gene expression in patients.